News headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 75 out of 100, meaning that recent press coverage is likely to have an effect on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

A number of research firms recently commented on CNAT. Zacks Investment Research downgraded Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, June 29th. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 24th. Finally, Aegis reissued a “buy” rating and issued a $11.00 price target on shares of Conatus Pharmaceuticals in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $13.25.

Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 0.49% during mid-day trading on Thursday, hitting $6.04. The stock had a trading volume of 416,159 shares. The firm’s market cap is $158.06 million. The stock has a 50-day moving average price of $5.61 and a 200 day moving average price of $5.55. Conatus Pharmaceuticals has a 12-month low of $1.45 and a 12-month high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.20. The company had revenue of $7 million during the quarter, compared to analysts’ expectations of $5.88 million. During the same quarter last year, the business posted ($0.35) earnings per share. Equities analysts anticipate that Conatus Pharmaceuticals will post ($0.71) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Conatus Pharmaceuticals (CNAT) Given Media Sentiment Rating of 0.15” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.